Breaking and building the wall: the biology of the blood-brain barrier in health and disease by Keller, A








Breaking and building the wall: the biology of the blood-brain barrier in
health and disease
Keller, A
Abstract: The blood-brain barrier (BBB) is a complex feature of brain endothelial cells that restricts
the passage of blood-borne molecules into the brain parenchyma, while ensuring the delivery of essential
nutrients and selected biomolecules. Brain vasculature is anatomically distinct from that of other organs
and comprises in addition to endothelial cells, pericytes and astrocytes, which collectively form the
neurovascular unit (NVU). This review focuses on the regulation of BBB properties by the NVU and
the periphery. A brief overview of cellular components of the NVU, and BBB characteristics will be
provided, with more emphasis placed on the molecular mechanisms involved in the development of brain
vasculature and human genetic diseases primarily affected by dysfunction of components of the NVU. In
addition, the regulation of brain vasculature by peripheral factors such as diet and systemic disease is
discussed.
DOI: 10.4414/smw.2013.13892




Keller, A (2013). Breaking and building the wall: the biology of the blood-brain barrier in health and
disease. Swiss Medical Weekly, 143:w13892. DOI: 10.4414/smw.2013.13892
Review article: Medical intelligence | Published 12 November 2013, doi:10.4414/smw.2013.13892
Cite this as: Swiss Med Wkly. 2013;143:w13892
Breaking and building the wall: the biology of the
blood-brain barrier in health and disease
Annika Keller
Institute of Neuropathology, Zürich University Hospital, Switzerland
Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
Summary
The blood-brain barrier (BBB) is a complex feature of
brain endothelial cells that restricts the passage of blood-
borne molecules into the brain parenchyma, while ensuring
the delivery of essential nutrients and selected biomolec-
ules. Brain vasculature is anatomically distinct from that of
other organs and comprises in addition to endothelial cells,
pericytes and astrocytes, which collectively form the neur-
ovascular unit (NVU). This review focuses on the regu-
lation of BBB properties by the NVU and the periphery.
A brief overview of cellular components of the NVU, and
BBB characteristics will be provided, with more emphasis
placed on the molecular mechanisms involved in the de-
velopment of brain vasculature and human genetic diseases
primarily affected by dysfunction of components of the
NVU. In addition, the regulation of brain vasculature by
peripheral factors such as diet and systemic disease is dis-
cussed.
Key words: blood-brain barrier; neurovascular unit;
endothelium; pericytes; astrocytes; brain pathology
Introduction
The human brain comprises only 2% of the total body
weight, but consumes 20% of the body’s metabolic energy.
In response to synaptic activity, blood flow within the brain
increases to meet the increased need for oxygen and nutri-
ents. Thus, proper functioning of the brain vasculature is
critical for the maintenance of optimal brain function. The
brain parenchyma is separated from blood within the cereb-
ral vasculature by the blood-brain barrier (BBB), and from
cerebrospinal fluid (CSF) by the CSF-brain barrier and
arachnoid-brain barrier. The BBB is a collective term for
brain-specific endothelial cell characteristics that restrict
the passage of blood-borne molecules into the brain, but
ensure delivery of essential nutrients and selected biomo-
lecules. In the animal kingdom, the BBB is already present
in invertebrates and it is hypothesised that the BBB has
developed to maintain ionic homeostasis around synapses
[1]. Also, most neurotransmitters show low BBB permeab-
ility, which allows separation of the peripheral from the
central pool of neurotransmitters. In invertebrates the BBB
is glial based. For example, in the fruit fly (Drosophila),
which has an avascular brain, perineural glia separate hae-
molymph and CNS. In phylogenetically more advanced in-
vertebrates such as Crustacea and Cephalopods, the CNS
is already vascularised and the BBB is formed by perivas-
cular glial cells [2]. During evolution, the barrier function
shifted to the endothelium, which is specialised to control
the exchange between the blood and brain, whereas glial
cells are specialised to control the local ionic environment
[2].
The principal features of the vertebrate BBB are closed
cell-cell junctions, a low rate of transcytosis and the ex-
pression of various solute carriers (SLCs) and adenosine
triphosphate-binding cassette (ABC) transporters. In addi-
tion to these special molecular characteristics, the blood
vessels in the brain are anatomically distinct. The first dif-
ference relates to the number and coverage of vascular
mural cells. The capillary bed of the brain vasculature has
a high density of pericyte coverage with full longitudinal
coverage by pericyte processes. In contrast, the vascular
smooth muscle cell coverage of arterioles and venules in
the brain is similar to other organs. The second difference
is that brain vasculature is covered by glial processes, the
so-called astrocyte end-feet. Another distinct characteristic
is the presence of Virchow-Robin spaces around penetrat-
ing arterioles that reside between the endothelial and glial
basement membrane. In addition, brain vessels are contac-
ted by microglia and nerve endings. The term neurovascu-
lar unit (NVU) is often used to describe brain blood vessels
to underline the intimate physical and functional connec-
tion between the brain tissue and blood vessels.
Another special feature of brain vessels is that they are
immunologically quiescent. Specifically, the expression of
leucocyte-adhesion molecules is low and few peripheral
leucocytes enter into the brain parenchyma.
In this review I will give a brief overview of the cellular
components of the NVU, BBB characteristics, and discuss
in more detail new insights about the molecular mechan-
isms involved in the development of brain vasculature. In
addition, I will provide examples of human genetic dis-
eases where dysfunction of components of the NVU is the
primary cause of the observed brain pathology. In addition,
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the regulation of brain vasculature by peripheral factors
such as diet or systemic disease is discussed.
Cellular and acellular components of
the neurovascular unit: development
and homeostasis
Endothelial cells
Endothelial cells that line the luminal side of blood vessels
enter the brain parenchyma early during neural tube devel-
opment. In the mouse, this takes place at embryonic day
9.5, starting in the hindbrain region [3]. The CNS is vas-
cularised by angiogenesis: by invasion of endothelial cells
from the pre-existing perineural vascular plexus. The mo-
lecular mechanisms that drive the vascularisation of neur-
al tissue are not fully understood. The master regulator
of vasculogenesis and angiogenesis, vascular endothelial
growth factor-A (VEGF-A), is upregulated by hypoxia and
secreted by neural cells, and serves as a chemoattractant for
vascular endothelial cells [3].
There is little known about the organ-specific signals re-
quired for the vascularisation and differentiation of the en-
dothelium. However, recent years have witnessed consid-
erable progress in our understanding of molecular mechan-
isms regulating brain vascularisation. Additional molecular
players that act in concert with VEGF-A, and are required
for brain angiogenesis have already been identified. For ex-
ample, expression of the tumour necrosis factor family re-
ceptors TROY and death receptor 6, essential for VEGF-in-
duced vascular sprouting, is induced by the Wnt signalling
pathway [4]. Whereas VEGF-A signalling is important for
the formation of vasculature in all organs, several brain-
specific signalling pathways responsible for brain vascu-
larisation have been identified. During early development,
brain-specific vascularisation signals are derived from de-
veloping neural tissue. For example, the canonical Wnt
signalling induced in endothelium was specifically shown
to be important for brain vascularisation. Deletion of lig-
ands Wnt7a/7b from neuroepithelial cells results in de-
fective brain angiogenesis and improper differentiation of
brain endothelium [5, 6]. Several other molecules either ex-
pressed or secreted by neuroepithelium regulate BBB de-
velopment and integrity (e.g. presenilin-1, retinoic acid)
[7, 8].
Another important signalling pathway for brain vascular-
isation is the transforming growth factor-β (TGF-β) path-
way. Targeted deletion of the integrin β8 chain from neur-
oepithelium results in defective brain vascularisation [9]. It
has been suggested that integrin αVβ8 expressed by neur-
oepithelium is needed for TGF-β activation [10]. The TGF-
β signalling in endothelium and pericytes is crucial for
angiogenesis and vessel maintenance (reviewed in [11]).
Consistent with this, it was recently demonstrated that ex-
pression of Tgfrb2 or Alk5 on endothelium and not on neur-
oepithelium was needed for proper CNS vascularisation
[12]. There are also endothelial-specific proteins that regu-
late brain angiogenesis in a cell-autonomous manner. The
endothelial expression of GPR124 was shown to be re-
quired for brain vascularisation by regulating endothelial
cell sprouting, migration and organ-specific differentiation
[13–15]. Interestingly, the expression of GPR124 on en-
dothelial cells is upregulated by TGF-β signalling [14].
The developing brain vasculature displays most of the BBB
characteristics very early in embryogenesis and is largely
impermeable to plasma proteins [16]. There are indications
that brain vasculature may possess regional differences or
at least different molecular mechanisms that guide brain
vessel development during embryonic development
[13–15].
As discussed above, the BBB characteristics of brain en-
dothelium are induced by neural tissue of the developing
brain. Additionally, maintenance of BBB characteristics is
achieved by signals emanating from other cell types sur-
rounding the endothelium, as will be exemplified below,
and this could explain why brain pathologies are associated
with breakdown of the BBB [17]. Little is known about
the turnover of cells at neurovascular unit; however, all en-
dothelial cells have the potential to proliferate in response
to angiogenic signals. The turnover of endothelium in nor-
mal tissue is measured in years [18].
Vascular smooth muscle cells and pericytes
Vascular smooth muscle cells (VSMCs) and pericytes, col-
lectively known as mural cells, enter the brain parenchyma
together with endothelial cells during angiogenesis. It is of
note that mural cells in the CNS have a distinct develop-
mental origin depending on anatomical location. In the an-
terior part of the brain, the mural cell population is derived
from the neural crest and in the posterior region, from the
mesenchyme [11]. It is not known if this leads to function-
al differences between these two developmentally different
mural cell populations.
Vascular smooth muscle cells surround small arteries, ar-
terioles and venules. It is believed that the blood flow of
brain vasculature is controlled at the level of arterioles, and
thus involves vessel constriction and relaxation controlled
by neurones and astrocytes that are mediated by VSMCs
[19]. Cerebral autosomal dominant arteriopathy with sub-
cortical infarcts and leucoencephalopathy (CADASIL) is
autosomal, dominant, and represents the most common
form of small vessel disease caused by the mutations in the
NOTCH3 gene [20]. Patients suffer from transient ischaem-
ic attacks and strokes at a very young age and subsequently
develop dementia. The clinical manifestations are restric-
ted to the brain, but arteriopathy can be seen in other organs
as well. In the normal brain, Notch3 is expressed by all
mural cells, VSMCs and pericytes [21]. The pathogenesis
of CADASIL is not fully understood, but aberrant Notch3
protein causes vascular fibrosis and VSMC degeneration,
which leads to ischaemic stroke [19].
Pericytes are perivascular cells that surround the endothe-
lium around capillaries [11]. Pericytes share the basement
membrane and are in direct contact with endothelium. The
CNS vasculature has almost 100% longitudinal pericyte
coverage. During development, the platelet-derived growth
factor-B (PDGF-B) / PDGF receptor β (PDGFRβ) sig-
nalling axis is important for pericyte recruitment and in-
vestment along developing vessels [11]. Maturation of en-
dothelial cells and pericytes during angiogenesis are intim-
ately linked, and defects in one cell type cause defects in
the other [22]. For example, abnormal endothelial polar-
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isation during development leads to poor recruitment of
pericytes [23]. Older BBB reviews propagated the view
that pericytes regulate the BBB at the level of endothelial
junctions, an assumption based on a few in-vitro studies.
However, careful analysis of cerebral vasculature and the
BBB characteristics of pericyte-deficient mice have shown
that pericytes regulate the BBB at the level of endothelial
transcytosis during early development and in adults [24,
25]. Absence of pericytes opens an endothelial transcytosis
route that lacks selectivity to the size and chemical nature
of tracers [24]. Furthermore, pericytes regulate the expres-
sion of endothelial adhesion molecules on the developing
vasculature, thus potentially regulating immune cell traf-
ficking [25].
Striking pathological changes observed in the brains of
pericyte-deficient animals lead to the formation of region-
specific calcium deposits [26]. Interestingly, the extent of
pericyte deficiency and BBB permeability correlates with
the severity of calcified lesions observed in the brains of
adult pericyte-deficient animals [26]. Thus, disturbances at
the BBB lead to changes in brain homeostasis. PDGFRβ
loss-of-function mutations were recently shown to repres-
ent one of the causes of familiar idiopathic basal ganglia
calcification (IBGC) [27]. IBGC is a rare autosomal dis-
ease with dominant inheritance, which manifests with bi-
lateral calcifications in various brain regions, mostly in
the basal ganglia. Clinical features include migraine, Par-
kinsonism, seizures, cognitive impairment and ataxia [28].
Some mutation carriers, despite the presence of calcified
lesions in the brain, remain asymptomatic [28]. The under-
lining cause of brain pathology of IBCG is not understood.
The calcified lesions are associated with blood vessels and
not within the neuropil [29]. It would be interesting to ex-
amine if affected individuals exhibit pericyte deficiency
and altered BBB characteristics. It is intriguing that sever-
al other genetic diseases affecting brain vasculature (dis-
cussed below, e.g. band-like calcification with simplified
gyration and polymicrogyria, Alexander disease) or caus-
ing neuroinflammatory disorders (e.g. Aicardi–Goutières
syndrome) or neurodegeneration (e.g., Parkinson’s disease)
are associated with intracranial calcifications [30].
Astrocytes
Astrocytes are CNS macroglial cells that provide another
distinct characteristic of brain blood vessels – certain as-
trocytes ensheath the entire abluminal side of blood vessels
with specialised processes called astrocyte end-feet. Astro-
cyte end-feet are slender processes, enriched with water
and potassium channels (e.g. aquaporin4 [Aqp4] and Kir
4.1, respectively) that are anchored to the basement mem-
brane of blood vessels via the dystroglycan complex [31].
Astrocytes are specified in the CNS relatively late during
development: in mice this takes place around birth, after
neuronal differentiation and initial CNS angiogenesis has
taken place [32]. Investment of blood vessels with astro-
cyte end-feet takes place postnatally and is completed two
weeks after birth in mice [33]. Early studies have suggested
that astrocytes are important for inducing the BBB prop-
erties of brain endothelial cells [34]. However, astrocytes
are unlikely to be important in the early induction of BBB
properties of brain endothelium, since developmentally,
they differentiate later. Nevertheless, astrocytes are import-
ant regulators of BBB properties. As yet, relatively little
is known about endothelium-astrocyte crosstalk and, even
today, only few studies have addressed which astrocyte-
derived signals regulate BBB development and mainten-
ance. In addition, the cellular and molecular mechanisms
leading to astrocyte end-feet formation and polarisation
largely remain elusive. However, a few clues are merging:
bone morphogenetic protein receptor type 1 (BMPR1A)
signalling in astrocytes is necessary for the investment of
astrocyte end-feet around vasculature [35], and pericyte-
derived signals regulate astrocyte end-feet polarization
[24]. Astrocytes have also merged as regulators of brain
endothelial immune quiescence. Astrocyte-derived Sonic
hedgehog (Shh) is needed for the active maintenance of en-
dothelial immune quiescence and the Shh-activated path-
way in endothelium has been shown to be deregulated in
multiple sclerosis patients [36]. The targeted elimination of
astrocytes that form astrocyte end-feet in experimental an-
imals is currently not possible. Astrocytes are a heterogen-
ous population and understanding of the specific function
of different astrocyte populations first requires identifica-
tion of the population-specific promoters to better under-
stand astrocyte functions also at the NVU. Some clues re-
garding the role of astrocytes in vivo in regulating the BBB
come from two human genetic diseases that specifically af-
fect astrocytes and cause BBB dysfunction.
One of the diseases that primarily affect astrocytes is Al-
exander disease, a fatal neurodegenerative disease with an
autosomal dominant inheritance pattern. It is caused by
mutations in the GFAP gene leading to intracellular accu-
mulation of glial fibrillary acidic protein, GFAP (Rosenth-
al fibres), which results in astrocyte death [37]. Alexander
disease onset (neonatal, juvenile, late) and severity of clin-
ical manifestations varies [37]. Neurodegeneration in Al-
exander disease is accompanied by BBB disruption and
capillaries show an increase in pinocytotic vesicles and oc-
casional damage of the endothelial basement membrane
[38].
The second disease that potentially affects astrocytes and
results in BBB impairment is megalencephalic leucoen-
cephalopathy with subcortical cysts (MLC), which is a
rare leucodystrophy caused by mutations in MLC1 or
GLIALCAM, and is characterised by chronic white matter
oedema [39, 40]. MLC1 is predominantly localised to
astrocyte-astrocyte contacts at astrocyte end-feet. The
function of this gene is not known; however, it is predicted
that MLC1 encodes a transmembrane protein that could
play a role in channel or transport function, and regulate
water transport in astrocytes [40].
In the periphery, excess of interstitial fluid is removed
from tissue by the lymphatic system [41]. The brain lacks
lymphatic vessels and thus lacks a specific pathway for
interstitial fluid clearance. However, recent research has
identified a so-called “glymphatic” pathway (derived from
glia and lymphatic) that facilitates movement of CSF from
the subarachnoid space along paravascular spaces that sur-
round penetrating arterioles. The clearance of interstitial
fluid occurs along venous drainage pathways [42]. The au-
thors of this study showed that the expression of water
channel Aqp4 on astrocytes facilitates interstitial solute
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clearance, suggesting that the bulk of interstitial fluid flow
is supported by astrocytic water transport [42]. Interest-
ingly, this pathway has been shown to transport amyloid β
from the brain into blood. The existence of interstitial fluid
drainage in the brain has been suggested before; however,
the drainage pathway was thought to be located only along
capillaries and arteries, and the flow of interstitial fluid was
considered to be opposite to the direction of blood flow
[43].
Thus, emerging data suggest that astrocytes at the NVU are
important regulators of brain fluid transport and that dis-
turbances in astrocyte end-feet function are associated with
oedema.
Perivascular macrophages
Perivascular macrophages are blood-derived phagocytotic
cells that reside in the perivascular spaces which surround
penetrating arterioles and are continuous with the sub-
arachnoid space (so-called Virchow-Robin space) [44].
These perivascular cells perform phagocytic functions and
regulate the immune response and lymphocyte entry into
brain parenchyma [45, 46].
Microglia
Microglial cells, as the name suggests, are of small size,
but the term is actually a misnomer, since they are now
considered to be the resident macrophages of the brain and
spinal cord.
Microglial cells invest the brain very early during develop-
ment, just before the endothelial cells invade and vascular-
ise the tissue. Developmentally, microglia are derived from
the yolk sac and thus have a different developmental origin
from perivascular macrophages residing in the Virchow-
Robin space [47, 48].
The biological functions of microglia during development
and the maintenance of the BBB and NVU has not been
vigorously investigated. In the adult organism, microglia
are important for maintaining endothelial integrity by sup-
porting damaged vessels and facilitating endothelial repair
in homeostasis and pathological conditions [48, 49]. The
molecular signalling pathways by which microglia support
the integrity of brain vessels remain elusive.
Basement membrane
Basement membrane is an important regulator of all epi-
thelial cells, and is essential for maintaining tissue integ-
rity. It is also crucial for the integrity of brain vasculature.
The main basement membrane components are fibronectin,
collagen IV, laminins, perlecans and nidogens [50]. The
basement membrane can be divided into two distinct parts
that have a different composition and cellular origin. The
endothelial basement membrane is deposited by endotheli-
al cells and pericytes/VSMCs, and the parenchymal base-
ment membrane by astrocytes [51]. Although the role of
the individual matrix molecules in the biology of blood
vessels is far from understood, some recent studies offer
insights. Mouse genetic studies have shown that basement
membrane is important for maintaining vessel stability and
the lack of individual matrix components is a cause of
haemorrhages due to vascular fragility [50]. In humans, ge-
netic defects in the gene encoding a component of collagen
IV (COL4a1, COL4a2) lead to nephropathy and haemor-
rhagic stroke [52–54]. Besides providing mechanical sta-
bility, the basement membrane is also essential for en-
dothelial cell polarisation and lumen formation [23]. Proper
endothelial polarisation is needed for the correct localisa-
tion of influx and efflux transporters. The vascular base-
ment membrane components agrin and laminins are im-
portant for anchoring astrocyte end-feet proteins Aqp4 and
Kir 4.1 via dystroglycan complex [31]. Merosin-deficient
congenital muscular dystrophy is an autosomal recessive
disorder caused by mutations in the LAMA2 gene that en-
codes a laminin alpha 2 chain [55]. Magnetic resonance
imaging (MRI) analysis of the brain in patients with
merosin-deficient congenital muscular dystrophy has
shown the presence of vasogenic oedema [55, 56]. It should
be interesting to determine whether in these patients the or-
ganisation of astrocyte end-feet is affected.
The blood-brain barrier characteristics
of brain endothelium
Cell-cell junctions
Endothelial cell-cell junctions of the brain are the most in-
tensively studied component of the BBB. In their seminal
work published in 1967, Reese and Karnovsky demon-
strated that the mammalian BBB is endothelium-based
[57]. Endothelial cell-cell junctions are composed of two
different types of junctions, adherens and tight junctions,
which are established by transmembrane proteins mediat-
ing homophilic extracellular interaction, and are connected
to the actin cytoskeleton inside the cell [58]. Of note, the
integrity of the cytoskeleton is also important for maintain-
ing BBB characteristics [59]. Adherens-type junctions are
composed of vascular endothelial (VE-) cadherin, which
is crucial for the integrity of all blood vessels in the body
[58]. In addition, endothelial cells express neural cadherin,
which is important for association with pericytes [60]. In-
tracellulary, adherens junctions connect to the cytoskeletal
protein complex consisting of many proteins (e.g. α-caten-
in, β-catenin, plakoglobin, p120, etc.). The molecular com-
position of this cytoplasmic complex is important for main-
taining vascular integrity, as demonstrated by studies where
individual elimination of these proteins (e.g. p120, afadin)
in endothelial cells resulted in embryonic death due to
defects in vascular development [58]. Tight junctions are
composed of several transmembrane proteins and the three
main components are claudins, occludins and junction ad-
hesion molecules (JAMs). In the cytoplasm, these molec-
ules are associated with a number of cytoplasmic proteins
including zonula occludens proteins [58]. It should be un-
derlined that cell-cell junctions are present in all endotheli-
al cells in the body; however, the junctions are closed in
the brain and restrict the passage of even ions. The junc-
tions are also needed to maintain endothelial polarisation
and thus the correct localisation of BBB transport proteins.
There are more than 20 claudins described, but only a few
are expressed by brain endothelium (e.g. claudin 1, 3, 5).
Today, little is known about the dynamic regulation of en-
dothelial junctions and how individual junctional compon-
ents interact with each other. However, the presence of VE-
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cadherin-based adherens junctions has been shown to be
crucial for the induction of tight junction components (e.g.
claudin 5) [61]. Tight junctions are composed of many dif-
ferent proteins and there seems to be extensive plasticity
in maintaining the closed junctions. For example, genetic
elimination of occludin, one of the components of tight
junctions, in mice does not result in an overt BBB phen-
otype [62]. In humans, mutations in the occludin gene
cause an autosomal recessive neurodevelopmental disorder
– band-like calcification with simplified gyration and poly-
microgyria [63]. Interestingly, both patients with this muta-
tion and mouse knockouts share similar features, with the
development of intracranial calcifications that are depos-
ited in the vicinity of blood vessels [63]. In humans, ho-
mozygous mutations of JAM3 cause intracerebral haemor-
rhages, subependymal calcification and cataracts [64].
Influx and efflux transporters
Because of the closed state of brain endothelial junctions,
brain endothelium is equipped with a transport system that
not only provides a selective route for nutrients, ions and
bioactive macromolecules, but also ensures elimination of
toxic molecules. These transporters are expressed in a po-
larised manner, which allows the effective exchange of mo-
lecules and ions between blood and the brain parenchyma
[65].
SLCs mediate influx of a variety of polar molecules into
brain parenchyma. The SLC protein family consists of ap-
proximately 300 genes and brain endothelial cells express
many different transporters that allow the influx of glucose,
amino acids, nucleosides, neurotransmitters (e.g. serotonin,
dopamine) and so on. It is intuitive that disturbances in
SLCs expression or function may have devastating effects
on brain development and function. Indeed, mutations in
GLUT1 gene, which encodes a facilitative glucose trans-
porter 1 (GLUT1) expressed by brain endothelial cells,
cause GLUT1 deficiency syndrome [66]. This syndrome is
caused by GLUT1 haplo-insufficiency and leads to mental
retardation accompanied by variety of neurological symp-
toms (e.g. ataxia) [66]. GLUT1 is expressed by brain en-
dothelial cells very early during brain angiogenesis and is
considered a feature of the early BBB. Recent studies in
zebrafish have demonstrated that, at least in lower verteb-
rates, GLUT1 expression is also required for the formation
of tight cell-cell junctions between endothelial cells during
brain angiogenesis [67]. In addition to disturbances in nu-
trient delivery, defective transport of bioactive molecules
can lead to a diseased state. SLC16A2 (MCT8) is a thyroid
hormone (T3) transporter and dysfunction of this transport-
er causes Allan-Herndon-Dudley syndrome [68]. Allan-
Herndon-Dudley syndrome is inherited in an X-linked re-
cessive manner and thus mostly affects males. More than
12 different mutations have been described in humans so
far, all leading to defects in thyroid hormone transport into
brain tissue [69]. Thyroid hormone by regulating, among
others, neuronal differentiation, myelination and synapse
formation, is critical for brain development during embryo-
genesis [68]. Affected individuals present with congenital
hypotonia with severe psychomotor delay [69].
The brain endothelium expresses many different ATP-driv-
en efflux pumps that are localised on the luminal side
of the endothelium [70]. The human genome encodes at
least 48 ABC-transporters [71], which restrict passage of
lipophilic xenobiotics that enter the endothelium via lipid-
mediated transport. The main BBB efflux transporters are
P-glycoprotein (ABCB1), multidrug resistance-associated
proteins (Mrp1, 2, 4, 5) and breast cancer-related protein
(Bcrp). The most studied example is the P-glycoprotein,
which is polyspecific and regulates the efflux of about half
of all commonly prescribed drugs. The expression of ABC
transporters is influenced by inflammation, and reduced ex-
pression of P-glycoprotein is observed in neurodegenerat-
ive diseases (e.g. Alzheimer’s, Parkinson’s) [70].
Transcytosis
Peptides and large molecular weight proteins enter the
brain via transcytosis. Transcytosis can be specific
(receptor-mediated) or non-specific (adsorptive-mediated).
Proteins and protein complexes that enter the brain via
receptor-mediated transcytosis include Fe-transferrin, lipo-
proteins, immunoglobulin G, insulin and leptin [65]. The
scarceness of endocytotic vesicles in brain endothelium has
been documented extensively by electron microscopic ana-
lysis; however, the regulation of the low transcytosis rate in
brain endothelium remains to be clarified. Interestingly, an
increased number of endothelial vesicles is the first change
seen in brain endothelium in response to hypoxia and has
been described as an early step in endothelial injury during
many pathological conditions (e.g. traumatic brain injury,
stroke). Recent research has identified pericytes as regulat-
ors of endothelial transcytosis in the CNS (see above “Vas-
cular smooth muscle cells and pericytes”) [24, 25].
Blood-borne gases such as oxygen and carbon dioxide dif-
fuse passively into the brain parenchyma along their con-
centration gradients. Accordingly, oxygenation and carbon
dioxide removal are both blood-flow dependent [65].
Vascular diseases affecting the central
nervous system
The list of diseases in which a vascular malformation or
malfunction leads to vessel dysfunction, rupture and subse-
quent brain damage is relatively long and includes cerebral
arteriovenous malformations, Moya-Moya syndrome and
familial forms of small vessel diseases of the brain causing
leucoencephalopathy, cerebral amyloid angiopathies,
cerebral cavernomas, intracranial aneurysms, etc. Muta-
tions in the NOTCH3, COL4a1 andCOL4a2 genes that are
responsible for hereditary vascular leucoencephalopathies
were discussed above. Most likely, the recent advances in
next generation sequencing and imaging technologies will
facilitate the identification of new genes causing cereb-
ral vascular diseases. For example, a novel form of dom-
inantly hereditary vascular leucoencephalopathy was de-
scribed that was mapped to chromosome 20q13 [72]. The
precise pathological mechanism of many CNS vascular
diseases is often poorly understood or not known at all.
However, the identification of the disease causing gene(s)
for several of these diseases has led to the generation of an-
imal models, which will help clarify the pathogenesis and
may lead to the generation of treatment strategies.
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Familial cerebral cavernous malformations (CCMs) repres-
ent a category of diseases where enormous progress in un-
derstanding the genetic causes and molecular mechanism
has been made during recent years. CCMs are vascular le-
sions that develop in the venous-capillary bed and are com-
posed of mulberry-like clusters of endothelial channels sur-
rounded by a thick endothelial basement membrane [73,
74]. CCMs are relatively common (1:200‒250) and can
be either sporadic or inherited. Familial forms of CCMs
are inherited in an autosomal dominant manner and are
caused by loss-of-function mutations in one of three genes:
CCM1, CCM2, and CCM3 [74]. Patients suffer from re-
current cerebral bleedings which cause neurological symp-
toms in little more than half of the CCM mutation carriers
[73]. Despite considerable progress in characterising the
functions of CCM proteins in endothelial cells, the underly-
ing cause of pathological alterations in CCM mutation car-
riers is still not clear. CCM proteins regulate many aspects
of endothelial biology (e.g. polarisation, branching, matur-
ation), which all could contribute to the lesion formation
[73].
The blood-brain barrier and
neurodegenerative and
neurological diseases
Breakdown of the BBB and NVU has been associated with
many neurological diseases that are beyond the scope of
this article. The reader is referred to several in-depth re-
views [17, 75]. Furthermore, the so called vascular hypo-
thesis postulates that vascular dysfunction is the primary
insult common to neurodegenerative diseases like
Alzheimer’s [76]. Currently, unequivocal demonstration of
NVU dysfunction as the primary cause of common neuro-
degenerative diseases is lacking. Additionally, various as-
pects of endothelial and NVU biology are altered in dif-
ferent neurodegenerative diseases, which most likely ex-
cludes a uniform, generic mechanism. For example, in
Alzheimer’s disease, the faulty clearance of the amyloido-
genic amyloid-beta forms via the brain vasculature seems
to be an important component of the disease pathogenesis.
Similarly, regional alterations in vascular permeability in
multiple sclerosis allow the ingress of peripheral leuco-
cytes, and thus the loss of immune quiescence in the brain
and spinal cord [76, 77].
The blood-brain barrier and
peripheral diseases
Whereas there is increased interest in the changes in the
BBB occurring in the setting of neurodegenerative diseases
(e.g. Alzheimer’s, amyotrophic lateral sclerosis), even less
is known about changes occurring in brain vasculature due
to peripheral diseases. Accordingly, I have listed a few ex-
amples of peripheral diseases, where changes in the brain
vasculature are recognized to result in neurological com-
plications. A mechanistic understanding of the BBB altera-
tions in these peripheral diseases is missing.
Acute liver failure
Acute liver failure with a sudden loss of hepatic function
triggers brain oedema, which is the main cause of death
[78]. Although the older literature suggests that cytotoxic
oedema is the major cause of brain oedema, recent studies
have demonstrated that vasogenic oedema is an important
pathogenic mechanism [79]. Interestingly, BBB breakdown
is accompanied by subtle changes in the brain endothelium
at the ultrastructural level. There is increased vesicularity
in the endothelium and altered architecture of the en-
dothelial cell-cell junctions [80–82]. It is believed that sys-
temic factors such as inflammatory cytokines and ammonia
are responsible for the changes in the BBB (reviewed in
[78]).
Posterior reversible encephalopathy syndrome
The posterior reversible encephalopathy syndrome (PRES)
is a recently described neurological syndrome character-
ised by headaches, visual disturbances and seizures. Re-
cognized causes of PRES include chemotherapy, renal fail-
ure, pre-eclampsia and the administration of immunosup-
pressive agents [83].
The pathophysiology of PRES is poorly understood, but in-
volves vasogenic oedema that is usually bilaterally sym-
metric, and localised to subcortical white matter of the pari-
etal and occipital lobes, but may also involve cerebellum
and brain stem [83]. Which component of the BBB and
neurovascular unit is affected is unknown. Interestingly, if
quickly diagnosed and treated, the oedema is reversible (as
suggested by the name of the syndrome).
Postoperative cognitive decline and anaesthesia
Patients undergoing surgery can develop postoperative
cognitive decline (POCD). Risk factors are advanced age
and comorbidities (e.g. metabolic disease, neurological dis-
ease), but the pathophysiology of POCD is not well un-
derstood. One emerging concept suggests that POCD is
caused by neuroinflammation evoked by peripherally pro-
duced proinflammatory cytokines in response to surgery
[84]. A recent study suggests that even surgical procedures
that do not involve the nervous system directly can induce
BBB dysfunction that leads to exstravasation of peripheral
monocytes causing neuroinflammatory changes and subse-
quent memory deficits [85]. Studies in animals have shown
that isofluorane anaesthesia can cause region-specific BBB
opening [86], but short-duration treatment does not cause
memory impairment [87].
The blood-brain barrier and
hypoxic conditions
The BBB is very sensitive to hypoxic conditions, and al-
terations in the BBB in response to hypoxia occur almost
immediately. The appearance of pinocytotic vesicles is ob-
served immediately, whereas the late effect is leakage
through the necrotic vessel wall [88]. Hypoxia accompan-
ies disorders like stroke, carbon monoxide poisoning, and
cardiac arrest. Interestingly, carbon monoxide poisoning
causes selective damage to the globus pallidus and cerebral
white matter, indicating that certain brain areas are more
vulnerable [89]. Also, high altitude is known to cause vaso-
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genic cerebral oedema [90]; however, the pathogenic
mechanisms leading to oedema remain elusive. Of poten-
tial significance is the upregulation of VEGF-A that has
been shown to be associated with low oxygen levels and
occurs after transient ischaemia [91, 92].
The blood-brain barrier and
metabolism
As discussed above, dysfunction of the BBB causes many
pathological conditions and is modified by diseases that
are not primarily caused by BBB dysfunction. Very little
is known about how metabolism influences the BBB at the
molecular level in the healthy organism. Although this is
a largely unexplored area, some insights are already emer-
ging. For example, the expression of ABC transporters is
increased at the transcriptional level by the presence of
xenobiotics and the activity of P-glycoprotein can be reg-
ulated by dietary components [70, 93]. The expression of
SLCs also changes in response to metabolic state. Under
normal circumstances, D-glucose is the main energy source
for the brain, but monocarboxylates can also be used, es-
pecially during the neonatal period, fasting and high-fat di-
ets [94]. The expression of monocarboxylate transporters
in the brain is regulated by obesity, high-fat diet and hy-
perglycaemia [95–97]. Interestingly, in hibernating animals
that have a lipid-based metabolism, the brain uses ketone
bodies as an energy source, which is accompanied by up-
regulation of MCT1 at the BBB [98]. Alternatively, fasting
has been shown to regulate another component of the brain
barrier, the brain-cerebrospinal fluid barrier, and to alter the
characteristics of the BBB at the level of endothelial junc-
tions. In response to lowered blood glucose, microvessels
that surround the hypothalamic median eminence and reach
the hypothalamic arcuate nucleus become fenestrated,
thereby facilitating the access of circulating signals to brain
nuclei regulating metabolism [99].
Conclusions and perspectives
From an evolutionary standpoint, the BBB is already
present in invertebrates, and developmentally the BBB
arises during the early phases of brain vascularisation. The
molecular development and regulation of the BBB is cur-
rently under intense investigation. Clearly, a collective ef-
fort from research groups working in different fields (vas-
cular biologists, physiologists, neurobiologists, etc.) is
needed to better understand the development and homeo-
stasis of complex structures such as the BBB and NVU.
The brain vasculature and vasculature in general is no
longer viewed as a simple conduit that delivers oxygen
and nutrients and passively restricts passage of blood-borne
molecules into the brain. Of note, the vasculature influ-
ences brain development and homeostasis and vice versa
– neural tissue regulates the development of brain vascu-
lature and its homeostasis.
The BBB and the NVU are complex structures that cannot
be adequately represented in in-vitro models. Recent ad-
vances in the comprehensive understanding of the molecu-
lar basis of BBB regulation and cell-cell signalling path-
ways at the NVU can largely be attributed to increased
studies using animal models. Although brain vascular de-
velopment and deregulation during pathological conditions
is better understood at the molecular and cellular level, the
majority of specific questions are unanswered. Which mo-
lecular signalling pathways regulate the components of the
BBB in vivo? How are BBB characteristics deregulated
during pathological conditions? How does diet and lifestyle
affect the BBB? How can the BBB be safely modified
in order to increase an effective drug concentration in the
brain? Hopefully, the next years will yield many “eureka
moments” for scientists investigating the BBB, which will
translate into the laboratory and clinical environments.
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